<p>Johnson & Johnson on Friday said it has applied for emergency use approval of its single-dose coronavirus vaccine in India.</p>.<p>J&J has tied up with domestic vaccine maker Biological E Ltd to produce the vaccines for the Indian market as well as globally.</p>.<p>“This is an important milestone that paves the way for bringing the company's single-dose Covid-19 vaccine to the people of India, and the rest of the world, through a collaboration with Biological E Limited,” a J&J statement said.</p>.<p><strong>Also read: <a href="https://www.deccanherald.com/business/business-news/jj-says-committed-to-bringing-its-covid-vaccine-to-india-1015545.html" target="_blank">J&J says committed to bringing its Covid vaccine to India</a></strong></p>.<p>When approved, the J&J vaccine would be the fifth vaccine that would be availability for use in India.</p>.<p>India's drug regulator has approved homegrown Covaxin, Serum Institute's Covishield, Russia-made Sputnik V and Moderna's vaccine for use in the country.</p>.<p>“Biological E will be an important part of our global supply chain network, helping to supply our Johnson & Johnson Covid-19 vaccine through the extensive collaborations and partnerships we have with governments, health authorities and organisations such as GAVI and the COVAX Facility,” the J&J statement said.</p>.<p>The EUA submission is based on topline efficacy and safety data from the Phase 3 ENSEMBLE clinical trial, which demonstrated that company's single-shot vaccine was 85% effective in preventing severe disease across all regions studied, and showed protection against Covid-19 related hospitalisation and death, beginning 28 days after vaccination, it added.</p>
<p>Johnson & Johnson on Friday said it has applied for emergency use approval of its single-dose coronavirus vaccine in India.</p>.<p>J&J has tied up with domestic vaccine maker Biological E Ltd to produce the vaccines for the Indian market as well as globally.</p>.<p>“This is an important milestone that paves the way for bringing the company's single-dose Covid-19 vaccine to the people of India, and the rest of the world, through a collaboration with Biological E Limited,” a J&J statement said.</p>.<p><strong>Also read: <a href="https://www.deccanherald.com/business/business-news/jj-says-committed-to-bringing-its-covid-vaccine-to-india-1015545.html" target="_blank">J&J says committed to bringing its Covid vaccine to India</a></strong></p>.<p>When approved, the J&J vaccine would be the fifth vaccine that would be availability for use in India.</p>.<p>India's drug regulator has approved homegrown Covaxin, Serum Institute's Covishield, Russia-made Sputnik V and Moderna's vaccine for use in the country.</p>.<p>“Biological E will be an important part of our global supply chain network, helping to supply our Johnson & Johnson Covid-19 vaccine through the extensive collaborations and partnerships we have with governments, health authorities and organisations such as GAVI and the COVAX Facility,” the J&J statement said.</p>.<p>The EUA submission is based on topline efficacy and safety data from the Phase 3 ENSEMBLE clinical trial, which demonstrated that company's single-shot vaccine was 85% effective in preventing severe disease across all regions studied, and showed protection against Covid-19 related hospitalisation and death, beginning 28 days after vaccination, it added.</p>
